Clinical Trial Update: Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial assessing single-dose pharmacokinetics and safety of belimumab 200 mg IV and 200 mg subcutaneous via auto-injector in healthy Chinese subjects; co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED | Results posted: 2020-12-28